Laurie Ailles

Dr. Laurie Ailles


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
KLKeith A. Lawson
Keith A. Lawson
CSCristovão M. Sousa
Cristovão M. Sousa
XZXiaoyu Zhang
Xiaoyu Zhang
EKEiru Kim
Eiru Kim
RARummy Akthar
Rummy Akthar
JMJason Moffat
Jason Moffat

30 March 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JSJocelyn M. Stewart
Jocelyn M. Stewart
PSPatricia A. Shaw
Patricia A. Shaw
CGCraig Gedye
Craig Gedye
MBMarcus Q. Bernardini
Marcus Q. Bernardini
BNBenjamin G. Neel
Benjamin G. Neel
LALaurie Ailles
Laurie Ailles
The cancer stem cell (CSC) model proposes that tumors have a hierarchical organization in which only some cells indefinitely self-renew and thereby sustain tumor growth. In addition, the CSC model requires that tumor-initiating cells (TICs) be prospectively isolatable on the basis of their phenotype. Previous studies have suggested that serous ovarian cancer (SOC) conforms to the CSC model, but these used arguably nonfidelitous immortalized cell lines, cultured primary cells, or passaged xenografts as the source of tumor cells. We developed a robust assay for quantifying TICs from primary SOC. Using this assay, we find that TICs are rare when assayed in either NOD/SCID or NOD/SCID/IL2Rγ −/− (NSG) mice. TIC frequency (TICf) varies substantially between patients, although it is similar in primary ovarian masses and omental metastases, suggesting that TICf is an intrinsic property of ovarian tumors. CD133 marks all TICs from several primary SOC cases. However, in other cases, substantial TIC activity is found in both the CD133 + and CD133 − fractions, whereas still other cases have exclusively CD133 − TICs. Furthermore, the TIC phenotype can change in xenografts: primary tumors in which all TICs are CD133 + can give rise to xenografts that contain substantial numbers of CD133 − TICs. Our results highlight the need for quantitative rigor in the evaluation of TICs and for caution when using passaged xenografts for such studies. Furthermore, although our data suggest that SOC conforms to the CSC hypothesis, the heterogeneity of the TIC phenotype may complicate its clinical application.

20 May 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AHAli Hussain
Ali Hussain
VVVeronique Voisin
Veronique Voisin
SPStephanie Poon
Stephanie Poon
CKChristina Karamboulas
Christina Karamboulas
NBNgoc Hoang Bao Bui
Ngoc Hoang Bao Bui
LALaurie Ailles
Laurie Ailles
Recent studies indicate that cancer-associated fibroblasts (CAFs) are phenotypically and functionally heterogeneous. However, little is known about CAF subtypes, the roles they play in cancer progression, and molecular mediators of the CAF “state.” Here, we identify a novel cell surface pan-CAF marker, CD49e, and demonstrate that two distinct CAF states, distinguished by expression of fibroblast activation protein (FAP), coexist within the CD49e+ CAF compartment in high-grade serous ovarian cancers. We show for the first time that CAF state influences patient outcomes and that this is mediated by the ability of FAP-high, but not FAP-low, CAFs to aggressively promote proliferation, invasion and therapy resistance of cancer cells. Overexpression of the FAP-low–specific transcription factor TCF21 in FAP-high CAFs decreases their ability to promote invasion, chemoresistance, and in vivo tumor growth, indicating that it acts as a master regulator of the CAF state. Understanding CAF states in more detail could lead to better patient stratification and novel therapeutic strategies.

29 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CGCraig A. Gedye
Craig A. Gedye
AHAli Hussain
Ali Hussain
JPJoshua Paterson
Joshua Paterson
ASAlannah Smrke
Alannah Smrke
HSHarleen Saini
Harleen Saini
LALaurie Ailles
Laurie Ailles
Cell surface proteins have a wide range of biological functions, and are often used as lineage-specific markers. Antibodies that recognize cell surface antigens are widely used as research tools, diagnostic markers, and even therapeutic agents. The ability to obtain broad cell surface protein profiles would thus be of great value in a wide range of fields. There are however currently few available methods for high-throughput analysis of large numbers of cell surface proteins. We describe here a high-throughput flow cytometry (HT-FC) platform for rapid analysis of 363 cell surface antigens. Here we demonstrate that HT-FC provides reproducible results, and use the platform to identify cell surface antigens that are influenced by common cell preparation methods. We show that multiple populations within complex samples such as primary tumors can be simultaneously analyzed by co-staining of cells with lineage-specific antibodies, allowing unprecedented depth of analysis of heterogeneous cell populations. Furthermore, standard informatics methods can be used to visualize, cluster and downsample HT-FC data to reveal novel signatures and biomarkers. We show that the cell surface profile provides sufficient molecular information to classify samples from different cancers and tissue types into biologically relevant clusters using unsupervised hierarchical clustering. Finally, we describe the identification of a candidate lineage marker and its subsequent validation. In summary, HT-FC combines the advantages of a high-throughput screen with a detection method that is sensitive, quantitative, highly reproducible, and allows in-depth analysis of heterogeneous samples. The use of commercially available antibodies means that high quality reagents are immediately available for follow-up studies. HT-FC has a wide range of applications, including biomarker discovery, molecular classification of cancers, or identification of novel lineage specific or stem cell markers.

1 October 2018 in Cell Reports
Verified
Journal Article
Open access
CKChristina Karamboulas
Christina Karamboulas
JBJeffrey P. Bruce
Jeffrey P. Bruce
AHAndrew J. Hope
Andrew J. Hope
JMJalna Meens
Jalna Meens
SHShao Hui Huang
Shao Hui Huang
LALaurie Ailles
Laurie Ailles
Overall survival remains very poor for patients diagnosed as having head and neck squamous cell carcinoma (HNSCC). Identification of additional biomarkers and novel therapeutic strategies are important for improving patient outcomes. Patient-derived xenografts (PDXs), generated by implanting fresh tumor tissue directly from patients into immunodeficient mice, recapitulate many of the features of their corresponding clinical cancers, including histopathological and molecular profiles. Using a large collection of PDX models of HNSCC, we demonstrate that rapid engraftment into immunocompromised mice is highly prognostic and show that genomic deregulation of the G1/S checkpoint pathway correlates with engraftment. Furthermore, CCND1 and CDKN2A genomic alterations are predictive of response to the CDK4and CDK6 inhibitor abemaciclib. Overall, our study supports the pursuit of CDK4 and CDK6 inhibitors as a therapeutic strategy for a substantial proportion of HNSCC patients and demonstrates the potential of using PDX models to identify targeted therapies that will benefit patients who have the poorest outcomes.

17 October 2022 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
JWJoseph Walton
Joseph Walton
KLKeith Lawson
Keith Lawson
PPPanagiotis Prinos
Panagiotis Prinos
AFAntonio Finelli
Antonio Finelli
CACheryl Arrowsmith
Cheryl Arrowsmith
LALaurie Ailles
Laurie Ailles